Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Arovella completes development for cell therapy platform, moves to large scale manufacturing
    • News

    Arovella completes development for cell therapy platform, moves to large scale manufacturing

    Biotech company Arovella Therapeutics (ASX: ALA), focused on developing its invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment, has achieved a major milestone. It has completed process development for its patent-protected manufacturing process required for large-scale Good Manufacturing Practice (GMP) manufacturing of its lead product, ALA-101. ALA-101 is an “off-the-shelf” CAR-iNKT cell

    Read More
    Public
  • Wellnex ventures into medicinal cannabis with it’s new Wellness Life brand
    • News

    Wellnex ventures into medicinal cannabis with it’s new Wellness Life brand

    Seeking expansion into the burgeoning medicinal cannabis market as part of the plant’s trend as a treatment for various common ailments, Wellnex Life (ASX: WNX) will debut its new Wellness Life cannabis brand next month.  The launch of Wellness Life will be supported by a collaboration with OneLife Botanicals and is bolstered by the appointment

    Read More
    Public
  • Harvest Technology launches Nodestream Live for remote video monitoring
    • News

    Harvest Technology launches Nodestream Live for remote video monitoring

    After a few board changes and a successful beta test program, software company Harvest Technology Group (ASX: HTG) is now ready to launch its remote video monitoring platform, Nodestream Live. This platform was previously introduced as the AVRLive Cloud. Nodestream Live is a cloud-based software designed to streamline and enhance remote video monitoring in bandwidth-constrained

    Read More
    Public
  • US shares slightly higher after late buying, XJO to open flat
    • Market Update

    US shares slightly higher after late buying, XJO to open flat

    Our market is set to open flat once again following another indecisive night in the U.S. For the past few days their market has retaken intraday losses to finish marginally in the green. Our market has translated this to our own sideward movement, and we should expect the same today. U.S futures are in the

    Read More
    Public
  • Visionflex exits PetYeti and GoBookings, forecasts 25% revenue growth
    • News

    Visionflex exits PetYeti and GoBookings, forecasts 25% revenue growth

    Virtual healthcare solutions company Visionflex (ASX: VFX), known for its telehealth devices, medical equipment, and software solutions, has shared a solid financial projection for FY24 following a name change and business divestments.  The Company exited PetYeti and GoBookings, completed in March and May 2024, respectively, to concentrate exclusively on the Visionflex business division. Following a

    Read More
    Public
  • AFT to launch Maxigesic Rapid in the United States after IV launch in Feb
    • News

    AFT to launch Maxigesic Rapid in the United States after IV launch in Feb

    Pharmaceutical company AFT Pharmaceuticals (ASX: AFP) has teamed up with pharma wholesaler Alexso to distribute Combogesic, or Maxigesic Rapid Tablets, in the United States, the largest pharma market in the world.  Maxigesic Rapid is a treatment for postoperative pain management. Clinical data showed that Combogesic IV provides more analgesia, or pain relief, than comparable doses

    Read More
    Public
  • «
  • ‹
  • 71
  • 72
  • 73
  • 74
  • 75
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.